Advanced Nanotherapies
Cleveland, US · Founded 2018 · Delaware corporation · 21 employees on LinkedIn
Advanced NanoTherapies (ANT) develops next-generation drug-coated balloons (DCBs) using nanotechnology to treat vascular disease. The company operates in the medical device and nanomedicine field, focused on cardiovascular and endovascular interventions.
Founders & leadership
Advanced Nanotherapies was founded in 2018 by Marwan Berrada-Sounni and Marwan Berrada.
MB
Marwan Berrada-SounniCo-founder
MB
Marwan BerradaFounder
MS
Mehdi ShishehborNamed on SEC filing
JC
Jerett CreedNamed on SEC filing
RG
Regina GrovesNamed on SEC filing
PU
Phillippe UrbainNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$9.9M disclosed across 2 rounds · 2019–2022
▶$9.2MraisedAug 2022 · 17 investors · BiotechnologyRule 506(b)
▶$9.2MraisedAug 2022 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mehdi ShishehborDirector
- Jerett CreedDirector
- Marwan Berrada-SounniExecutive Officer, Director
- Regina GrovesDirector
- Phillippe UrbainDirector
- Offering amount
- $9.2M
- Amount sold
- $9.2M
- Minimum investment
- $50K
- Proceeds to insiders
- $600K
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$640KraisedAug 2022 · 10 investors · BiotechnologyRule 506(b)
▶$640KraisedAug 2022 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mehdi ShishehborDirector
- Marwan Berrada-SounniExecutive Officer, Director
- Regina GrovesDirector
- Phillippe UrbainDirector
- Jerett CreedDirector
- Offering amount
- $640K
- Amount sold
- $640K
- Minimum investment
- $4K
- Proceeds to insiders
- $250K
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Integrated Nanotherapeutics Inc.3 shared keywordsIntegrated Nanotherapeutics (INT) is a preclinical-stage biotech developing antigen-specific immune tolerance therapies using lipid nanoparticles to treat autoimmune diseases such as Type 1 Diabetes, Multiple Sclerosis, and allergy. Its lead program, INT-101, targets Type 1 Diabetes, and the company also offers an LNP-based drug delivery platform for small molecules and nucleic acids.
ロゴマーク：AIRNA3 shared keywordsAIRNA develops RNA editing therapeutics aimed at providing functional cures for patients with rare diseases and common conditions. The company works in the genetic medicines and biotech space.
Neurona Therapeutics3 shared keywordsNeurona is a clinical-stage biotherapeutics company developing allogeneic, off-the-shelf regenerative neural cell therapies that integrate into neural circuits to treat chronic neurological disorders. Its pipeline includes neuronal, glial, and gene-edited cell therapy candidates led by NRTX-1001, an inhibitory neuron therapy for epilepsy.</parameter>
<parameter name="founders">[]
Companies competing with Advanced Nanotherapies for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Advanced Nanotherapies do?
- Advanced NanoTherapies (ANT) develops next-generation drug-coated balloons (DCBs) using nanotechnology to treat vascular disease. The company operates in the medical device and nanomedicine field, focused on cardiovascular and endovascular interventions.
- Who founded Advanced Nanotherapies?
- Advanced Nanotherapies was founded by Marwan Berrada-Sounni, Marwan Berrada in 2018.
- How much funding has Advanced Nanotherapies raised?
- Advanced Nanotherapies has disclosed $9.9M raised across 2 rounds.
- Where is Advanced Nanotherapies headquartered?
- Advanced Nanotherapies is headquartered in Cleveland, US.